Genome-based healthcare

Genome (personal genome)-based healthcare (genome diagnosis and examination) technology can predict and diagnose individual physical characteristics or diseases by prepping and analyzing genetic information from the blood, saliva, and epithelial cells of individuals. Clinomics Inc. (hereinafter, Clinomics) has 10 types of products that predict genetic-based physical characteristics or diseases, including Geno-P, Geno-D, and Geno-Dx. Clinomics' genomic testing service has a variety of test service (product) groups for each disease (phenotype) and is designed to cover a wide range of areas such as cancer, complex diseases, rare diseases, nutrition, aging, and ancestor analysis. In addition, each test service group consists of a prediction and pre-test, neonatal screening, carrier test, diagnostic test, and other tests (nutritional test), so it has the advantage of providing customized test services to various markets and consumers in Korea and abroad.

Liquid biopsy platform

The liquid biopsy platform is a technology that analyzes the patient's body fluids (mainly blood, but urine and saliva as well) to detect and analyze circulating tumor cells (CTCs) or cell-free DNA (cfDNA) in the blood. Clinomics has a differentiated technology from other liquid biopsy companies in Korea and abroad. Other companies are focusing on either CTC or cfDNA, but Clinomics developed a fully automated CD-PRIME™ (blood centrifuge) called OPR-2000 in 2020, and this can detect both CTC and cfDNA at the same time. Our other related clinical products include OPR-1000, CTC-SOLO, CTC-DUO, OPR-2000, LBx1 and LBx2.

Cancer Diagnosis/Monitoring

Cancer diagnosis/monitoring products provide information for cancer treatment or prescriptions by analyzing the mutation status of cancer-causing genes (multi-genes) in the tissue or blood of cancer patients, and continuously monitoring the mutation status after treatment. Clinomics' current cancer diagnosis/monitoring products include Cancer-PRIME™, Liver Cancer Panel, and Maternal Cancer Panel. Based on its genetic diagnostic panel manufacturing technology, Clinomics has developed a gene analysis panel that can diagnose and monitor lung/liver/gynecological cancers and solid cancers by analyzing cfDNA and CTC obtained from patients' blood as well as target cancer-related genes, and which is currently undergoing clinical and performance verification. Even when the same anticancer drug is administered, some patients completely defeat cancer, and other patients experience no effect or resistance, which is due to individual differences in the patient's genetic characteristics and variations. Companion diagnosis (CDx) is used for diagnosing these individual genetic characteristics and mutations and selecting an appropriate drug. Companion diagnosis is the basis of personalized medical care, such as increasing the response rate of drugs, minimizing side effects, improving the quality of life for patients, reducing unnecessary prescriptions, and contributing to the health of insurance finances. Clinomic soffers a variety of companion diagnostic services, including specific and sensitive detection of ROS1 gene fusion of non-small cell lung cancer through related know-how, tools, and its product, NSCLC. The services currently available include ROS1 (non-small cell lung cancer), PIK3CA (breast cancer), and KRAS (lung/colon cancer).

Early diagnosis based on multi-omics

Multi-omics-based early diagnosis products predict (or diagnose early) the possibility of disease by synthesizing information such as individual genomic information from blood, as well as epigenomic, proteomic, expressionic, and metabolic information. Clinomics is currently developing early diagnosis products for diseases such as suicide/depression and heart/myocardiology diseases, and its early diagnosis products for cancer cover colorectal cancer, lung cancer, and stomach cancer. Early diagnosis of cancer (lung, stomach and colon cancer) requires epigenome analysis (or exogenous analysis) to overcome the limitations of previously well-known single nucleotide polymorphism (SNP) and somatic mutation-based research results, and to enable accurate diagnosis predictions according to the different characteristics of various carcinomas. The above multi-omics data analysis is useful for identifying cancer influences and correlations between omics' and omics by types and enables the discovery of the most accurate biomarkers required for early cancer diagnosis. In addition, Clinomics performs analysis and testing based on non-invasive liquid biopsies using blood and gastric juices, so it is possible to implement various practical technologies for early cancer prediction, early diagnosis, etc.

Bio BigData Center

There is a growing need for cloud commercialization services with high-capacity computing hardware for genomic/health/medical information in order to standardize, analyze, process, and store increasing bio and medical data. High-speed transmission technology for the fast transmission of tens/hundreds of terabytes or more of genomic data to domestic/external networks and services that can efficiently handle (manage) complex programs and DBs is essential in the big data field. With the advent of the convergence era, the need for integrated big data analysis and data distribution of bio/health information and medical information is increasing, and Clinomics is responding quickly to this trend by establishing its own BBC (abbreviation for bio big data center).